Skip to main content
OpenTrials
Completed

NCT Number: NCT04199624

Assessment of Gastric pH Changes Induced by Ascorbic Acid Tablets

This study evaluates the use of ascorbic acid, vitamin C, to temporary reduce gastric pH in individuals with omeprazole induced hypochlorhydria. All participants will receive ascorbic acid tablets to measure the change in gastric pH.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–30 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

Indiana University School of Medicine

Indianapolis, Indiana, 46202, United States

About this study

Elevation of gastric pH in patients with hypochlorhydria can reduce the solubility of weakly basic drugs. This may lead to poor and unpredictable systemic exposure for poorly soluble drugs. For example, extent of absorption of the kinase inhibitors, dasatinib (Sprycel) and erlotinib (Tarceva), is reduced by up to 61% and 46% respectively in patients on acid-reducing agents (ARAs). This pilot study is to evaluate the use of ascorbic acid, vitamin C, to temporary reduce gastric pH in individuals with omeprazole induced hypochlorhdyria. Using pH/impedance testing, we are seeking to determine the magnitude and duration of pH change upon administration of 1000 mg of ascorbic acid in healthy subjects with proton-pump inhibitor induced hypochlorhydria. The results from this study will be used to evaluate the use of ascorbic acid as a drug-drug interaction mitigation strategy.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy, young males age 18-30 years with no prior history of gastrointestinal disease or symptoms.

Exclusion criteria

  • Hypochlorhydria (baseline use antacids, antisecretory medications, or surface agents including proton-pump inhibitors, H2 blockers, or sucralfate).
  • Current or previous history of gastrointestinal disease including gastroesophageal reflux disease, Barrett's esophagus, peptic ulcer disease, dyspepsia, gastroparesis, bacterial overgrowth, microscopic colitis, gastric intestinal metaplasia or metaplastic atrophic gastritis, gastric neuroendocrine tumors, helicobacter pylori infection, inflammatory bowel disease (Crohn's disease or ulcerative colitis), celiac disease, visceral cancer, chronic infectious disease, immunodeficiency, uncontrolled thyroid disease, history of liver disease).
  • History of gastric bypass or other abdominal surgeries excluding cholecystectomy or appendectomy > 6 months prior to study initiation.
  • Radiation therapy to the abdomen.
  • Pregnant females.
  • Ingestion of any prescription, over-the-counter, or herbal medications which may affect study interpretation.
  • Currently a smoker
  • Antibiotic use within the last 3 months

Treatment and study plan

Omeprazole 20mg

Drug

Omeprazole twice daily x 5 days

Vitamin C

Dietary Supplement

Ascorbic acid x 1 on day 5

Primary outcomes

  1. Change in gastric pH and duration of gastric pH \status

    Time frame: From time of inpatient appointment to thirteen months after that time point.

    Gastric pH measurements will be continuously monitored throughout the study using a catheter-based pH monitoring system. Gastric pH versus time data will be collected for five hours.

Secondary outcomes

  1. Intestinal microbiome profile, intestinal metabolomic profile

    Time frame: From time of initial stool drop-off to thirteen months after that time point.

    To explore the correlation between physiologic responses in gastric pH with features of the intestinal microbiome and microbial metabolites (e.g. metabolome).

Sponsors and collaborators

Lead sponsor

Indiana University

Other

Collaborators

  • Butler University
  • Hala Fadda

Registry information

Important dates

Study start
2021
Primary completion
2023
Study completion
2023
First posted
Dec 16, 2019
Registry last updated
Sep 22, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.